BRAF V600E

Parallel translational work using cfDNA-based liquid biopsy has mapped a spectrum of secondary kinase-domain mutations that underlie acquired resistance, informing the development of next-generation FGFR2-selective inhibitors (eg, lirafugratinib) and combination strategies with EGFR/ERBB blockade. Collectively, these data underscore the need for comprehensive molecular profiling and innovative umbrella trial designs to optimise targeted therapy in this rare, biologically heterogeneous malignancy.

Recent advances highlight a rapid surge in positive immunotherapy trials across different head and neck cancer entities, with clinical benefit observed both when immune checkpoint inhibitors are moved earlier in the disease course and when they are combined with agents targeting resistance mechanisms or enabling more precise drug delivery to tumors.

Consistently, the Gsk3αβ knock-in mutations do not change the transcriptional programme induced by V600EBraf, except for 3 genes (Ephx4, Eif2b3 Ppp1r13l) whose expression is significantly altered, potentially contributing to the short-term increase in crypt hyperplasia. Overall, our data show that therapeutic strategies targeting GSK3αβ phosphorylation at serines 21/9 are not worthwhile options for V600EBRAF colorectal cancers.

Building on this synthesis, we propose that the insights gained from well-characterized lymphoproliferative disorders may serve as a valuable foundation for investigating related yet poorly understood conditions, such as HCL. Furthermore, given the scarcity of both biological samples and reliable preclinical models for rare hematological malignancies, we highlight the strategic role of European biobanks in providing access to well-annotated clinical samples-an essential resource for fostering interdisciplinary collaboration and enabling advanced experimental modelling.

P2, N=56, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

In conclusion, this multicenter study suggests that most MS are of myelomonocytic/monoblastic origin, a high proportion of them are NPM1 mutated, and may lack expression of MPO and CD34. NPM1 mutation-specific antibodies should be integrated into the diagnostic panels for MS or LC, while IRF8 and PU.1 are not recommended as they cannot distinguish MS from histiocytic neoplasms.

The majority of cutaneous epithelioid/pleomorphic rhabdomyosarcoma show clinical, genetic, and epigenetic profiles similar to melanoma, suggesting that a major subset represents transdifferentiated melanoma.

The patient was later hospitalized for "recurrent hemoptysis" and received pemetrexed adjuvant chemotherapy combined with cisplatin...Consequently, a targeted therapy regimen combining low to moderate doses of dabrafenib and trametinib was initiated...Moreover, only one low-grade immune-related adverse event was observed during the course of immunotherapy. Patients with advanced NSCLC and BRAF mutations who cannot tolerate targeted therapy are expected to benefit from immunotherapy.

The vaccine was safe, well-tolerated, and immunogenic. Optimization of vaccines that include agonistic CD40 antibody is needed to enhance immunogenicity. Induction of a multifunctional CD4+ T cell response to mBRAF supports targeting shared mutated neoantigens with melanoma vaccines.

P3, N=257, Active, not recruiting, Pfizer | Trial completion date: Mar 2026 --> Aug 2026

Success in this arena will hinge on utilitarian biomarker-based cohort selection, the discovery of fresh immunogenic epitopes, and the meticulous design of synergistic treatment combinations. The synergistic leverage of genomic, transcriptomic, and immune landscape dissection, coupled with cutting-edge engineered lymphocyte platforms and engineered oncolytic vectors, may finally position immunotherapy as an unassailable pillar of bespoke medicine for advanced thyroid carcinomas.

Gastric LCH patients have a good prognosis and long overall survival when the cancer is a localized lesion. However, systemic involvement may necessitate chemotherapy, and regular follow-up is recommended.